DEDIFFERENTIATED LIPOSARCOMA

This adverse event was reported 40 times

These drugs are most commonly taken by patients reporting DEDIFFERENTIATED LIPOSARCOMA:

# Drug Count
0 CYTARABINE 10
1 FLUDARABINE PHOSPHATE 10
2 DOXORUBICIN 6
3 REGORAFENIB 6
4 BUSULFAN 5
5 DOCETAXEL 5
6 DOCETAXEL ANHYDROUS 5
7 GEMCITABINE HYDROCHLORIDE 5
8 METHOTREXATE SODIUM 5
9 GEMCITABINE 4
See all common drugs associated with DEDIFFERENTIATED LIPOSARCOMA

DEDIFFERENTIATED LIPOSARCOMA is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 LAROTRECTINIB 1 0.0011
1 REGORAFENIB 6 0.0005
2 ADALIMUMAB-AFZB 1 0.0004
3 BUSULFAN 5 0.0003
4 FLUDARABINE PHOSPHATE 10 0.0003
5 ELOTUZUMAB 1 0.0002
6 CYTARABINE 10 0.0002
7 STANDARDIZED SENNA CONCENTRATE 2 0.0002
8 SELINEXOR 1 0.0001
9 CANDESARTAN CILEXETIL 3 0.0001
See all drugs enriched for association with DEDIFFERENTIATED LIPOSARCOMA